Cerevel Therapeutics Holdings, Inc. (CERE)
- Previous Close
41.90 - Open
41.81 - Bid 30.10 x 200
- Ask 53.82 x 200
- Day's Range
41.80 - 42.19 - 52 Week Range
19.59 - 43.59 - Volume
672,507 - Avg. Volume
1,398,524 - Market Cap (intraday)
7.639B - Beta (5Y Monthly) 1.49
- PE Ratio (TTM)
-- - EPS (TTM)
-2.67 - Earnings Date May 1, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
43.40
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.
www.cerevel.comRecent News: CERE
Performance Overview: CERE
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CERE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CERE
Valuation Measures
Market Cap
7.64B
Enterprise Value
7.02B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
11.34
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-16.86
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-24.73%
Return on Equity (ttm)
-72.44%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-432.84M
Diluted EPS (ttm)
-2.67
Balance Sheet and Cash Flow
Total Cash (mrq)
990.96M
Total Debt/Equity (mrq)
71.36%
Levered Free Cash Flow (ttm)
-198.16M